



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 280 555 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73,74
- (51) Int Cl.:
A61K 45/06 ^(2006.01) **A61K 31/635** ^(2006.01)
A61K 31/55 ^(2006.01)
- (48) Corrigendum issued on:
28.06.2006 Bulletin 2006/26
- (86) International application number:
PCT/US2001/009265
- (45) Date of publication and mention
of the grant of the patent:
17.05.2006 Bulletin 2006/20
- (87) International publication number:
WO 2001/082920 (08.11.2001 Gazette 2001/45)
- (21) Application number: **01922578.8**
- (22) Date of filing: **22.03.2001**

(54) **PHARMACEUTICAL COMPOSITION COMPRISING FUROSEMIDE AND CONIVAPTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE**

PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND FUROSEMID UND CONIVAPTAN
ZUR BEHANDLUNG DES KONGESTIVEN HERZVERSAGENS

COMPOSITION PHARMAZEUTIQUE CONTENANT DU FUROSEMIDE ET DU CONIVAPTAN POUR
LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE CONGESTIVE

- | | |
|--|--|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR</p> <p>(30) Priority: 03.05.2000 US 201431 P</p> <p>(43) Date of publication of application:
05.02.2003 Bulletin 2003/06</p> <p>(73) Proprietor: Astellas Pharma Inc.
Tokyo 103-8411 (JP)</p> <p>(72) Inventors:
• BAKKER-ARKEMA, Rebecca Guggemos
Ann Arbor, MI 48105 (US)
• PRESSLER, Milton Lethan
Saline,
Michigan 48176 (US)</p> | <p>(74) Representative: HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)</p> <p>(56) References cited:
• P.S.CHAN E.A. : "VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist " ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 449, 1998, pages 439-443, XP000991018
• S.K.SWAN E.A.: "Interaction between VPA-985 and ADH (V2) antagonists and furosemide" JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, 1999, page 124A XP000989912
• T.TANEJA E.A.: "Current status of acute intravenous therapy for chronic heart failure exacerbations" CONGESTIVE HEART FAILURE, vol. 5, no. 5, 1999, pages 199-207,215, XP001053331</p> |
|--|--|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 280 555 B8